Lutonix
Lutonix develops drug-coated balloon catheters that deliver paclitaxel to arterial walls during a single short inflation for peripheral vascular intervention. Founded in 2007 in Maple Grove, Minnesota, the company serves interventional cardiologists and vascular surgeons treating peripheral artery disease.
- Company typePublic
- Founded1897
- HeadquartersMaple Grove, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lutonix does
Lutonix is a Maple Grove, Minnesota-based medical device company founded in 2007 that develops drug-coated balloon (DCB) catheters for peripheral vascular intervention. Its lead product, the Lutonix DCB, delivers paclitaxel to the arterial wall during a single, short inflation, targeting the femoropopliteal and broader peripheral artery disease market served by interventional cardiologists and vascular surgeons. The company is privately held, operates with 11–50 employees, and is headquartered at lutonix.com.
Lutonix's core technology is a proprietary paclitaxel-coated balloon catheter platform in which the anti-restenotic drug is transferred to the vessel wall during balloon expansion, eliminating the need for a permanent implant. The platform relies on drug-coating formulation know-how, balloon mechanics, and combination-product (drug-device) engineering. The firm has been backed by a syndicate of healthcare-specialist venture investors, having raised approximately $35 million across three financing rounds between 2007 and 2010 (a $5M founding round in April 2007, a $20M Series 2 led by Versant Ventures in October 2008 with Delphi Ventures, RiverVest, and U.S. Venture Partners, and a $10M Series 3 in December 2010).
Lutonix's revenue model is typical of an early-commercial, single-product Class III combination-product device company: unit sales of the DCB catheter to hospitals, cath labs, and ambulatory surgery centers, typically procured through group purchasing organizations and specialty distribution channels. Pricing details, contract structures, and named end customers are not disclosed in the available input data. The firm operates as a standalone private entity in the provided sources, with Jay W. Schmelter listed as a director on its board.
Lutonix firmographics
Firmographics- Name
- Lutonix
- Legal name
- Becton, Dickinson and Company
- Website
- https://lutonix.com
- Company type
- Public
- Founded year
- 1897
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lutonix develops drug-coated balloon catheters that deliver paclitaxel to arterial walls during a single short inflation for peripheral vascular intervention. Founded in 2007 in Maple Grove, Minnesota, the company serves interventional cardiologists and vascular surgeons treating peripheral artery disease.
- Ownership category
- akta.pro rank
Lutonix industry classification
Industry- Product category
- Peripheral Vascular Intervention Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
Keywords
Where Lutonix is headquartered
LocationHeadquarters
- HQ city
- Maple Grove
- HQ country
- United States
- HQ region
- North America
Markets served
Lutonix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Lutonix product offering
Product offeringCore offering
Lutonix develops the Lutonix DCB, a drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. The product combines balloon angioplasty mechanics with localized drug delivery to treat peripheral arterial disease, and is sold as a medical device to hospitals and interventional clinicians.
Differentiator
Problem solved
Functional benefit
Brands
- BD Pyxis: Automated dispensing solutions and pharmacy technologies system for medication availability, security and control.
- BD ChloraPrep
- BD Nexiva
- BD HemoSphere Alta
- BD Aptra
- PureWick
- Rotarex
- Phasix
- Magic3 Go
- VitaWave Plus
- Bardex I.C.
- BD Hypak
Products and services
- Lutonix DCB (Drug-Coated Balloon Catheter)
Companies that use Lutonix
Customer profileIdeal customer profiles1 record
Lutonix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lutonix partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
Lutonix competitors and assessment
Company assessmentEmerging players
- Penumbra: Penumbra's peripheral vascular thrombectomy and embolization devices compete in the same PAD treatment pathway as Lutonix DCB, addressing overlapping patient populations.
- AngioDynamics: AngioDynamics offers peripheral thrombectomy and ablation products that are complementary/competitive in PAD treatment pathways where Lutonix DCB is also used.
- SurModics: SurModics develops proprietary drug-coating technology used in third-party DCB programs, making it a comparable emerging player in the DCB enabling-technology space adjacent to Lutonix's paclitaxel delivery platform.
Broad incumbents
- Becton, Dickinson and Company (BD): BD owns Lutonix via the C.R. Bard acquisition and is the parent company commercializing the product globally; it is the broad incumbent that controls Lutonix's commercial roadmap and distribution.
- Abbott Vascular: Abbott competes in peripheral vascular intervention via drug-eluting stents (Xience Sierra) and other endovascular devices, providing an overlapping but broader portfolio versus the Lutonix DCB focus.
- Cardinal Health: Cardinal Health distributes and supplies peripheral vascular devices and consumables, providing an indirect but adjacent competitor/distributor relationship to Lutonix within hospital vascular service lines.
- Teleflex: Teleflex operates a broad vascular and interventional access portfolio (including Arrow and specialty catheters) that overlaps with Lutonix's peripheral intervention customers and call points.
Direct peers
- Medtronic: Medtronic markets the IN.PACT Admiral drug-coated balloon, the leading paclitaxel DCB in the femoropopliteal segment and Lutonix DCB's most direct head-to-head competitor in peripheral vascular intervention.
- Philips (Philips IGTD): Philips sells the Stellarex DCB in peripheral vascular disease and competes head-to-head with Lutonix for femoropopliteal and AV fistula share via its image-guided therapy division.
- Boston Scientific: Boston Scientific offers the Ranger DCB and a broad peripheral vascular portfolio, competing directly with Lutonix DCB in femoropopliteal interventions and AV access.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Lutonix social profiles
Digital presenceLutonix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lutonix leadership team
Management profileNumber of profiles
Profiles1 record
Lutonix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lutonix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lutonix
What does Lutonix do?
Lutonix develops the Lutonix DCB, a drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. The product combines balloon angioplasty mechanics with localized drug delivery to treat peripheral arterial disease, and is sold as a medical device to hospitals and interventional clinicians.
Is Lutonix a public or private company?
Lutonix is a public company. It is classified as corporate owned and is currently operating.
When was Lutonix founded?
Lutonix was founded in 1897. It employs 11 to 50 people.
Where is Lutonix based?
Lutonix is headquartered in Maple Grove, United States, in the North America region.
Who are Lutonix's main competitors?
Emerging players on record are Penumbra, AngioDynamics and SurModics. Broad incumbents are Becton, Dickinson and Company (BD), Abbott Vascular, Cardinal Health and Teleflex. Direct peers are Medtronic, Philips (Philips IGTD) and Boston Scientific.
Does Lutonix have an API?
No public API is recorded for Lutonix.
What industry is Lutonix in?
Lutonix's product category is Peripheral Vascular Intervention Devices. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.